NOVEL ANGIOGENIC MOLECULAR TARGET AND USES THEREOF

Use of an inhibitor (A) of protein FKBP65 to prepare a composition for treating cancer; for inhibiting angiogenesis, and for treating diabetic retinopathy, macular degeneration, atherosclerosis, arthritis, rheumatoid polyarthritis, psoriasis and disorders of wound healing. Independent claims are als...

Full description

Saved in:
Bibliographic Details
Main Authors FABIEN SCHWEIGHOFFER, SILVERE PETIT, EMMANUEL VALENTIN
Format Patent
LanguageEnglish
Published 14.07.2004
Edition7
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Use of an inhibitor (A) of protein FKBP65 to prepare a composition for treating cancer; for inhibiting angiogenesis, and for treating diabetic retinopathy, macular degeneration, atherosclerosis, arthritis, rheumatoid polyarthritis, psoriasis and disorders of wound healing. Independent claims are also included for the following: (1) polypeptides (I) having any of 3 sequences (644, 601 and 431 amino acids (aa), reproduced) or their fragments; (2) nucleic acid (II) that encodes (I); (3) nucleic acid probes (III) that can detect the FKBP65 gene, or corresponding RNA, by selective hybridization, containing at least part of any of 4 sequences (2641 (1), 2824 (3), 2698 (5) or 2630 (7) bp, reproduced), or their fragments; (4) single-stranded primer (IV) that contains 6-50 nucleotides (nt) complementary to at least part of sequence (1), (3), (5) or (7), to their complements or their border regions; (5) method for detecting a disease, or predisposition, or for monitoring or staging, by detecting the presence, amount or distribution of FKBP65 protein, its expression, altered forms of it, or the corresponding mRNA; (6) method for selecting, screening, characterizing, optimizing or producing active compounds by determining their capacity to interact with FKBP65 (gene or protein) or to modulate its expression or activity; (7) cloning or expression vector that contains (II); and (8) recombinant cells containing the vector of (7) or (II).
Bibliography:Application Number: AU20030300656